Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release

Diabetes Care

Volumn 37, Issue 4, 2014, Pages 912-921

  Garvey, W Timothy ^a   Ryan, Donna H ^b   Henry, Robert ^c   Bohannon, Nancy J V ^d   Toplak, Hermann ^e   Schwiers, Michael ^f   Troupin, Barbara ^g   Day, Wesley W ^g  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MONTEFIORE MEDICAL CENTER   (United States)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

^f Medpace ^*  (United States)

^g Menlo Park and VIVUS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; PHENTERMINE; PLACEBO; TOPIRAMATE; ANTIOBESITY AGENT; DELAYED RELEASE FORMULATION; FRUCTOSE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; COMORBIDITY; CONSTIPATION; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DYSGEUSIA; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INTENTION TO TREAT ANALYSIS; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PARESTHESIA; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SINUSITIS; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; XEROSTOMIA; ANALOGS AND DERIVATIVES; COMPLICATION; DELAYED RELEASE FORMULATION; DIABETES MELLITUS, TYPE 2; LIFESTYLE; MIDDLE AGED; PREDIABETIC STATE;

ANTI-OBESITY AGENTS; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; FRUCTOSE; HUMANS; LIFE STYLE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PHENTERMINE; PLACEBOS; PREDIABETIC STATE;

EID: 84897883613     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-1518     Document Type: Article

References (40)

1. Centers for Disease Control and Prevention. Diabetes public health resource: 2007 national diabetes fact sheet. Atlanta, GA, Centers for Disease Control and Prevention, 2007
2. The facts about diabetes: a leading cause of death in the U.S. Bethesda, MD, National Diabetes Education Program. Available from http://ndep.nih.gov/ diabetes-facts/index.aspx. Accessed 14 May 2012
3. American Diabetes Association. Standards of medical care in diabetes - 2012. Diabetes Care 2012;35(Suppl. 1):S11-S63
4. Nathan DM, Davidson MB, DeFronzo RA, et al.; American Diabetes Association. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007;30:753-759 (Pubitemid 46354366)
5. Alberti KG, Eckel RH, Grundy SM, et al.; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-1645
6. Bakris G, Stockert J, Molitch M, et al.; STAR Investigators. Risk factor assessment for new onset diabetes: literature review. Diabetes Obes Metab 2009;11:177-187
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
8. Grundy SM, Cleeman JI, Daniels SR, et al.; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752 (Pubitemid 41532612)
9. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM; San Antonio Heart Study. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio Heart Study. Diabetes Care 2003;26:3153-3159 (Pubitemid 37339513)
10. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-1428 (Pubitemid 40523737)
11. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-544
12. Tuomilehto J, Lindström J, Eriksson JG, et al.; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350 (Pubitemid 32378388)
13. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403 (Pubitemid 34437694)
14. Deedwania PC, Volkova N. Current treatment options for the metabolic syndrome. Curr Treat Options Cardiovasc Med 2005;7:61-74 (Pubitemid 40894656)
15. Karam JG, McFarlane SI. Update on the prevention of type 2 diabetes. Curr Diab Rep 2011;11:56 -63
16. UK Prospective Diabetes Study 7. UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients, UKPDS Group. Metabolism 1990;39:905-912
17. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J. Long-term non-pharmacological weight loss interventions for adults with prediabetes. Cochrane Database Syst Rev 2005;18:CD005270
18. National Heart, Lung, and Blood Institute. Identification, evaluation, and treatment of overweight and obesity in adults, 2000 [Internet]. Available from http://www.nhlbi.nih.gov/guidelines/obesity/prctgd-c.pdf. Accessed 8 February 2013
19. Bariatric surgical and procedural interventions in the treatment of obese patients with type 2 diabetes: a position statement from the International Diabetes Federation Taskforce on Epidemiology and Prevention: International Diabetes Federation Consensus Panel, 2011 [Internet]. Available from http://www.bakeridi.edu.au/Assets/Files/IDF-Position-Statement-Bariatric- Surgery.pdf. Accessed 8 February 2013
20. Colquitt JL, Picot J, Loveman E, Clegg AJ. Surgery for obesity. Cochrane Database Syst Rev 2009;15:CD003641
21. Hussain SS, Bloom SR. The pharmacological treatment and management of obesity. Postgrad Med 2011;123:34-44
22. Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 2012;367:695-704
23. Kofman MD, Lent MR, Swencionis C. Maladaptive eating patterns, quality of life, and weight outcomes following gastric bypass: results of an Internet survey. Obesity (Silver Spring) 2010;18:1938-1943
24. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012;20:330-342
25. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:1341-1352
26. Garvey WT, Ryan DH, Look M, et al. Twoyear sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95:297-308
27. Brownell K. The LEARN Program for Weight Management. Dallas, TX, The Life Style Company, 2000
28. Sutherland JP, McKinley B, Eckel RH. The metabolic syndrome and inflammation. Metab Syndr Relat Disord 2004;2:82-104 (Pubitemid 39545406)
29. Elobeid MA, Padilla MA, McVie T, et al. Missing data in randomized clinical trials for weight loss: scope of the problem, state of the field, and performance of statistical methods. PLoS ONE 2009;4:e6624
30. Rubin DB. Multiple Imputation for Nonresponse in Surveys. Wiley Series in Probability and Mathematical Statistics. New York, John Wiley & Sons, 1987
31. Schafer JL. Analysis of Incomplete Multivariate Data (Monographs on Statistics and Applied Probability 72). London, Chapman & Hall/CRC, 1997
32. Hamman RF, Wing RR, Edelstein SL, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006;29:2102-2107 (Pubitemid 44871194)
33. Laaksonen DE, Lindström J, Lakka TA, et al.; Finnish Diabetes Prevention Study. Physical activity in the prevention of type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 2005;54:158-165 (Pubitemid 40105108)
34. Knowler WC, Fowler SE, Hamman RF, et al.; Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677-1686
35. Lindström J, Ilanne-Parikka P, Peltonen M, et al.; Finnish Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006;368:1673-1679 (Pubitemid 46048554)
36. Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008;371:1783-1789 (Pubitemid 351697954)
37. Lara-Castro C, Fu Y, Chung BH, Garvey WT. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol 2007;18:263-270 (Pubitemid 46743049)
38. Reaven GM. Insulin resistance: the link between obesity and cardiovascular disease. Med Clin North Am 2011;95:875-892
39. Wing R, Gillis B. The Diabetes Prevention Program's Lifestyle Change Program. Pittsburgh, PA, University of Pittsburgh, 1996. Available from http://www.bsc.gwu.edu/dpp/lifestyle/DPP-duringcore.pdf. Accessed 8 February 2013
40. Garvey WT, Najarian T, Peterson CA. Significant weight loss with controlledrelease phentermine/topiramate (PHEN/TPM CR) is associated with significant reductions in use of concomitant medications for cardiometabolic diseases over 108 weeks. Obesity 2011;19:S176